Professional Documents
Culture Documents
,-
a
,*, 3A%,
e
&
@: '#
*
w
w
Z,'' -
.#,
*ry
*
4F
RECENT TRENDS IN
POULTRY
PRODUCTION
S, P.TIWARI O, P.DINANI
Chapter 21
lntroduction
Transgenic chickens hold promise in many commercial and
industrial applications beyond the intrinsic value as model systems in
biological research. Chickens deposit large amounts of proteins into
their eggs. A transgenic chicken could conceivably function as a bio-
reactor for the production of commercially or pharmaceuticaliy
important proteins, which are difficult or impossible to produce
economically in prokaryotic systems. Gene transfer technology may
also prove to be a useful complement to traditional poultry breeding
methods in the improvement of commercially important production
traits, such as growth and disease resistance. Both intra and inter-
species transfer could be used in poultry to introduce genes controlling
desirable physiological functions unavailable in the existing pool of
genetic variation. The quality of the product can be modified by
biotechnolory; a transgenic layer chicken can produce more eggs with
less cholesterol or a genetically engineered broiler chicken can produce
lean meat or with a favourable lipid profile to reduce health risk to the
consumer.
content derives from the ovalbumin gene with four other proteins
(lysozyme, ovomucoid, ovomucin and conalbumin) present at levels
of 50 milligrams or greater (Gilbert, 1984). Modern layers produce 330
eggs per year so three or four hens producing one gram per egg would
yield a kilogram of raw product annually. The naturally sterile egg
also contains egg white protein at high concentration allowing for a
long shelf-life of recombinant protein without loss in activity (Harvey
et al., 2002).
Methods of transgenesis
A number of strategies designed to allow the manipulation of the
avian genome have been investigated with varying degrees of success.
They are:
and therefore, to give rise to a complete organism. The PGC are the
precursors of the cells, which compose the germline. They are excellent
candidates for genetic modification. This cell mediated method involves
prior insertion of the desired DNA sequence by homologou.s
iecombination into an in aitro co-culture of ES or PG cell along with
the vector having a desirable gene sequence. Genetically, modified ES
and PG cells can also be produced by infection with replication-
defective retroviral vectors, by lipofection and by electroporation. The
transfected cells can be separated by markers and then incorporated
into a recipient embryo at the blastocyst stage of development. The
result is a chimeric chicken in the founder generation. If some of the
transfected embryonic stem cells also contribute to the germline of the
chimera, it can serve as the founder of a transgenic line. A chimeric
intermediate produces both transgenic and normal birds in the first
generation. The transgenic offspring breed true from the second
generation onwards.
Origin of Primordial Germ Cells: ln chicken embryos, PCC arise in
the epiblast at the centre of the Stage X blastoderm and migrate to the
hypoblast at Stage 12. During gastrulation, they continue to migrate
anteriorly and laterally until they arrive at the germinal crescent after
18 h of incubation. With the establishment of the embryonic vascular
system, they migrate into the circulating blood and reach the peak
number of PGC at Stage 13 to 14 (about 50 h of incubation). Then,
PGC migrate through the blood vessels (Ginsburg and Eyal-Giladi,
1986) and finally arrive at the germinal ridge and begin to proliferate.
In adults, PGC differentiate into oogonia or spermatogonia (Fujimoto
et nl., 1976).
Isolntion and culture: The PGCs can be isolated from different
embryonic tissues, such as the germinal crescent at HH stage 4,
extraembryonic blood vessels at embryonic day 2.2 and embryonic
gonads at embryonic days 5 to 6. Because of their extra-embryonic
origin and specific migration routes, PGC could be collected and
transferred at four regions: the centre of blastoderm at Stage X, the
germinal crescent during gastrulation, the early vascular system at
Stage 13 to L4, and the germinai ridge after 72 h of incubation.
Applicntion of genome-editing in aaian trnnsgenesis: The genome
editing tools and their applications in avian transgenesis is reviewed
by Hwang and Han (2018). The total germ-line transrnission efficiency
from targeted PGCs is approximately 0.1% due to natural homologous
recombination; the efficiency can be improved to 8% by using TALEN
Advances in Avian Transgenesis 279
Biopharming
Transgenic poultry has the potential to be used for the production
of pharmaceutical and industrial proteins in eggs (Ivarie, 2003) and
several successfully generated transgenic chickens as a bioreactor have
been reported (Zhu et al., 2005; Lillico et al., 2007). Recently, genome-
editing tools, such as transcription activator-like effector nuclease
(TALEN) and clustered regularly interspaced short palindromic repeat
(CRISPR)/ CRlSPR-associated protein (CRISPR/ Cas) have been
adapted as promising methods for developing avian model (Park et
nl., 2014; Oishi et al., 201,6; Taylor et nl., 2017). Chicken bioreactors
provided, among others, human erythropoietin (Koo et a1.,2010),
interferon alpha- 2b (Rapp et al., 2003), interferon beta-1a (Lillico ef
al., 2007), monoclonal antibodies (Kamihira et al., 2005) and
granulocyte colony stimulating factor (G-CSF) (Kwon et a1.,2008).
Since 2011, the U.S. Food and Drug Administration Centre for
Drug Evaluation and Review (CDER) and the Centre for Bioiogics
Evaluation and Review (CBER) combined have approved 62
recombinant therapeutic proteins (Lagass6 et al., 20L7). Many
biopharmaceuticals are produced using bacterial, yeast or mammalian
cell culture expression systems. Current mammalian cell-culture based
systems are increasingly optimised and industrialized (Shukla et al.,
2017). The first drug produced in a transgenic animal, antithrombin
III in goat milk, was approved for use by the European Medicines
Agency in 2006 and the FDA in 2009 (Kues and Niemann, 2011).
Almost seven years later, the FDA has approved a second
biopharmaceutical product made using a transgenic chicken. The
product is Alexion Pharmaceuticals' 'Kanuma' (sebelipase alfa) for
the treatment of patients with the rare disease lysosomal acid lipase
Advances in Avian Transgenesis 283
Conclusions
The benefits of biotechnology are plenty. Animal transgenesis raises
some ethical problems as embryo manipulation and transgenes
themselves may reduce animal welfare. Thoughtful ethical decision-
making is needed in the biotechnology industry, scientists, policy-
makers, and the public. The safety of the product should be ensured
which should be approved through a science-based regulatory process.
Another important question is whether human welfare the only
consideration? What about the welfare of other life forms? Rather,
should scientists focus oninaitro (cultured in a lab) transgenic methods
to limit the use of using live animals/ birds to maximum extent possible
to alleviate animal suffering? Efficient methods for producing
transgenic animals expressing recombinant proteins have been
developed over the past 20 years. On positive side, transgenic animals
offer opportunities to significantly reduce costs in producing mAb and
human recombinant proteins with post-translational modifications that
closely match those of human proteins. Recent technical advances,
namely gene editing has opened new avenues. We can anticipate many
developments on efficiency of techniques in avian transgenesis that
will provide a critical tool to increase productivity in the poultry and
biopharmaceutical industries in the future.
References
Anzar, M. and Buhr, M. M. 2006. Spontaneous uptake of exogenous DNA by bull
spermatozo a. Theriogenology, 65 : 683-90.
284 Recent Trends in Poultry Production
Fujimoto, T., Ukeshima, A. and Kiyofuji, R.1.976. The origin, migration and
morphology of the primordial germ cells in the chick embryo. The Aruilomical
Record, 1,85: 139-45.
Gilbert, A. B. 1984. Egg albumen and its formation, Physiology and biochemistry
of the domestic fowl (Bell, D.]., Free, B.M. eds), pp. 1291-1329, Academic
Press, Cambridge, Massachusetts, USA.
Ginsburg, M. and Eyal-Giladi, H. 1986. Temporal and spatial aspects of the
gradual migration of primordial germ cells from the epiblast into the
germinal crescent in the avian embryo . loumal of Embryology and Exyeimental
Morphology,95: 53-7L.
Cordon, J. and Ruddle, F. 1981. Integration and stable germ line transmission of
genes inj ected into mouse pronuclei. S ci en c e, 21, 4: 1244- 46 .
Garcia-Vazquez,F. A., Garcia-Roseilo, E., Gutierrez-Adan, A. and Gadea,l.2009.
Effect of sperm treatment on efficiency of EGFP-expressing porcine embryos
produced by ICSI-SMGT . Therio genolo gy, 7 2 : 506-1 8.
Advances in Avian Transgenesis 285
Kamihira, M. Ono, K., Esaka, K., Nishijima, K., Kigaku,R. et a1.2005. High-level
expression of single-chain Fv-Fc fusion protein in serum and egg white of
genetically manipulated chickens by using a retroviral vector. lournal of
Virology, 79 : 1,0864-74.
Kang, S. J., Choi, J. W., Kim, S. Y, Park, K. J., Kim, T .M., et a1.2008. Reproduction of
wild birds via interspecies germ cell transplantation. Bioogy of
Rep r o du ction, 79 : 931-37 .
Li, 2.D., Deng, H., Liu, C. H., Song, Y. H., Sha, 1., et n1.2002. Production of duck-
chicken chimeras by transferring early blastodermal cells. Poultry Science
81:1360-64.
Lillico, S. G., Sherman, A., Mcgrew, M. J., Robertson, C. D., Smith, J., et a|.2007.
Oviduct-specific expression of two therapeutic proteins in transgenic hens.
PIJAS, 104:1771-76.
Liu, C., Khazanehdari, K. A., Bhaskar, V., Saleem, S., Kinne, J., Wernery, U., et ril.
2012. Production of chicken progeny (Gallus gallus domesticus) from
interspecies germline ghimeric duck (Anas domesticus) by primordial germ
ceil. Transfer Biology of Reproduction, 86 : 1-8.
Love, ]., Gribbin, C., Mather, C., and Sang, H. 1994.Transgenic birds by DNA
microinjecti on. B io technolo gy, 12: 60 -63.
Macdonaid, J.,Taylor, L., Sherman, A., Kawakami, K., Takahashi, Y., Sang, FI.M.,
et crl. 2012. Efficient genetic modification and germ-line transmission of
primordial germ cells using piggyBac and Tol2 transposons, PNAS, 109:
El466-72.
McGrew, M.]., Shermary A., Ellard, F. M., Lillico, S. G., Gilhooley, H. J., et al.2004.
Efficient production of germline transgenic chickens using lentiviral
vectors. EMB O REorts, 5:728-33.
Mizuarai, S., Ono, K., Yamaguchi, K., Nishijima, K., Kamihira,M. et a|.2001.
Production of transgenic quails with high frequency of germline
transmission using VSV-G pseudotyped retrovirai v ector. Biochemicnl and
B i ophy si c al Res e nr ch CommtLni c ati o n s, 286 : 45 6- 63.
Mozdziak, P. E., Borwornpinyo, S., McCoy, D. W. and Petitte, J. N. 2003.
Development of transgenic chickens expressing bacterial b-galactosidase.
D eo elopment al D ynami cs, 226: 439 -45.
Oishi, I., Yoshi, K. Miyahara, D. Kagami, H. and Tagami, T.2016. Targeted
mutagenesis in chicken using CRISPR/Cas9 system. Scientific Reports,6'.
239-80.
Pancer, 2., Snapir, N., Robinzon, 8., Friedman, A. and Eyalgiladi, H. 1989.
Recovery of ova and their re-insertion into the hen's oviduct through a
fistula. British Poultry Science, 30:953-57.
Park, T. S. and Han, J. Y.2012. piggyBac transposition into primordial germ cells
is an efficient tool for transgenesis in chickens. PNAS, L09:9337-41
Park, T. S., Lee, H. J., Kim, K. H., Kim, J. S. and Han, j. y.201"4. Targeted gene
knockout in chickens mediated by TALENs. PNAS, 177:12716-21.
Perry, M. M. 1988. A complete culture system for the chick embryo, Nature,331,:
70-72.
Petitte N., Clark, M. E., Liu, C., Verrinder Gibbins, A. M. and Etches, R. j. 1990.
J.
Production of somatic and germline chimeras in the chicken by transfer of
eariy blastodermal cells, Deaelopment, 108: 185-89.
Advances in Avian Transgenesis 287
Reynaud, G.1969. The transfer of turkey primordial germ cells to chick embryos
by intravascular injection. journal of Embryology and Experimental
Morphology, 21:485 - 07.
Yi,y., Noh, M.]. and Lee, K.H. 2011. Current advances in retrovirai gene
therapy. Current Gene Therapy ,11: 218-28.
ZhrL,vande Lavoir MC, Albanese J, Beenhouwer DO, Cardarelli PM, et ol. 2005.
Production of human monoclonal antibody in eggs of chimeric
chickens. N atur e B i o t e chnol o gy, 23 : 11,59 - 69 .
oEItr